Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Accenture Plc (NYSE: ACN) declined 0.33 percent to close at $75.87 a share Thursday. The stock traded between $75.62 and $76.73 on volume of 5.01 million shares traded. The company reported net revenues were $7.1 billion for the fiscal fourth quarter, an increase of 4.0 percent when compared to a year ago. Shares of Accenture have gained approximately 3.0 percent year-to-date.
Get more information on Accenture and free access to the in-depth equity report at:
www.FiveStarEquities.com/ACN
KiOR Inc. (NASDAQ: KIOR) shares soared 57.92 percent to close at $2.89 a share Thursday. The stock traded between $1.85 and $3.10 on volume of 8.65 million shares traded. The company has announced plans to double production capacity at its Columbus, Mississippi, cellulosic fuels facility. Shares of KiOR have fallen approximately 55.0 percent year-to-date.
Get more information on KiOR and free access to the in-depth equity report at:
www.FiveStarEquities.com/KIOR
Nike Inc. (NYSE: NKE) shares increased 2.06 percent to close at $70.34 a share Thursday. The stock traded between $69.15 and $70.49 on volume of 6.80 million shares traded. The company reported revenues from continuing operations were $7.0 billion for the first quarter of fiscal 2014, an increase of 8.0 percent when compared to a year ago. Shares of Nike have gained approximately 36.0 percent year-to-date.
Get more information on Nike free access to the in-depth equity report at:
www.FiveStarEquities.com/NKE
Nektar Therapeutics (NASDAQ: NKTR) shares increased 3.28 percent to close at $13.85 a share Thursday. The stock traded between $13.41 and $14.19 on volume of 1.54 million shares traded. The company reported NKTR-181 failed to meet its primary endpoint in a recent Phase 2 study Shares of Nektar Therapeutics have gained approximately 87.0 percent year-to-date.
Get more information on Nektar Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/NKTR
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com